Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $12.71, but opened at $12.09. Mesoblast shares last traded at $11.97, with a volume of 79,906 shares.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $18.00.
Check Out Our Latest Analysis on MESO
Mesoblast Stock Down 3.1%
The company's fifty day moving average price is $11.22 and its 200-day moving average price is $14.03. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.
Hedge Funds Weigh In On Mesoblast
Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its holdings in shares of Mesoblast by 86,566.7% during the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock valued at $51,000 after purchasing an additional 2,597 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Mesoblast by 1,503.3% during the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock valued at $5,756,000 after purchasing an additional 272,595 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Mesoblast by 41.1% during the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock valued at $129,000 after purchasing an additional 1,891 shares during the last quarter. LPL Financial LLC lifted its holdings in shares of Mesoblast by 7.7% during the fourth quarter. LPL Financial LLC now owns 38,882 shares of the company's stock valued at $770,000 after purchasing an additional 2,795 shares during the last quarter. Finally, Strategic Financial Concepts LLC purchased a new position in shares of Mesoblast during the fourth quarter valued at approximately $2,744,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
